Maintaining Wellness and Safety for Halloween 2021

Rezafungin (Rezzayo; Cidara Therapeutics Inc, Melinta Therapeutics LLC) is the first new treatment option approved for individuals with candidemia and invasive candidiasis in more than a decade.

Findings from the ongoing Adult Respiratory Syncytial Virus phase 3 trial suggest RSVPreF3 OA vaccine is effective and safe for individuals aged 60 years and older.

Persistently pursuing valued goals and adjusting those goals in response to setbacks or obstacles may help explain how some individuals with chronic pain maintain their mental wellbeing.

Findings from the AFFIRM trial found increased risks after stopping oral anticoagulant therapy after rhythm control, and the same is true for stopping treatment with oral anticoagulants after successful ablation.

Ideally, older patients receive vaccinations by October, but disease activity often peaks in February or March.

US adults have a slightly stronger preference for fewer adverse events in relation to pediatric COVID-19 vaccination, study results show.